The survival time of non-small cell lung cancer usually depends on the patient’s own physical condition, tumor stage, treatment effect, etc. The five-year survival rate is between 20%-80%. If stage I non-small cell lung cancer can tolerate surgery, the five-year survival rate is about 70%-80%. If the body cannot tolerate surgery, Stage I non-small cell lung cancer can be treated with stereotactic high-dose radiotherapy, and the five-year survival rate is around 70%-80%. Non-small cell lung cancer can be treated with immunotherapy, targeted drug therapy, radiation therapy, chemotherapy, and biotherapy. These treatments can well hinder the metastasis and growth of NSCLC and prolong the life of patients. If patients have gene mutation, EGFR gene or ALK gene mutation, they can choose the corresponding drug targeted therapy. After targeted therapy for stage IV patients, the effective rate is around 70% and the five-year survival rate is around 20%. It is recommended that non-small cell lung cancer patients go to professional hospitals in time and listen to the advice of professional doctors.